1. Home
  2. BVFL vs MDXH Comparison

BVFL vs MDXH Comparison

Compare BVFL & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BV Financial Inc.

BVFL

BV Financial Inc.

HOLD

Current Price

$19.40

Market Cap

168.6M

Sector

Finance

ML Signal

HOLD

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$2.08

Market Cap

149.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
BVFL
MDXH
Founded
1873
2003
Country
United States
Belgium
Employees
N/A
N/A
Industry
Savings Institutions
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
168.6M
149.0M
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
BVFL
MDXH
Price
$19.40
$2.08
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$7.67
AVG Volume (30 Days)
13.2K
186.6K
Earning Date
01-28-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
31.19
N/A
EPS
1.43
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$30.78
Revenue Next Year
N/A
$18.31
P/E Ratio
$13.64
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.65
$1.40
52 Week High
$19.88
$5.33

Technical Indicators

Market Signals
Indicator
BVFL
MDXH
Relative Strength Index (RSI) 57.36 19.34
Support Level $18.22 $1.90
Resistance Level $19.81 $2.30
Average True Range (ATR) 0.49 0.23
MACD 0.08 -0.08
Stochastic Oscillator 92.89 9.02

Price Performance

Historical Comparison
BVFL
MDXH

About BVFL BV Financial Inc.

BV Financial Inc is a federally-chartered savings and loan holding company engaged in offering traditional financial services to consumers and businesses. The company offers savings, interest checking, money market, personal and business checking, non-interest checking, education savings, small business checking, and business checking and certificates of deposit and IRA certificates of deposit. The Company's sources of revenue are derived from interest and dividends earned on loans and investment securities.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: